Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain

Next Previous
X
Search
Trial Profile

A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elagolix (Primary) ; Estradiol/norethisterone
  • Indications Dysmenorrhoea; Endometriosis; Pelvic pain
  • Focus Registrational; Therapeutic Use
  • Sponsors AbbVie

    • Most Recent Events

    • 15 Dec 2023 Status changed from active, no longer recruiting to completed.
    • 14 Feb 2023 Planned End Date changed from 30 Jan 2023 to 3 Jan 2024.
    • 15 Jul 2019 Planned End Date changed from 30 Mar 2021 to 30 Jan 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top